source
- Merck ADC, licensed from China, hits mark in first big global trialThe endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.BioPharma Dive · 2mo ago↗ source
- Regeneron reaches $125M Parabilis deal for hard-to-catch drug targetsAs Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as $2.2 billion. Parabi…Endpoints · 2mo ago↗ source
- Design Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from ChinaPlus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich's ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improveme…